Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis-Reference-Cited by-同舟云学术

Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis

Published:2015-06-22 Issue:4 Volume:15 Page:273-279
ISSN:1474-7758
Container-title:Practical Neurology
language:en
Short-container-title:Pract Neurol

Author:

Scolding Neil,Barnes David,Cader Sarah,Chataway Jeremy,Chaudhuri Abhijit,Coles Alasdair,Giovannoni Gavin,Miller David,Rashid Waqar,Schmierer Klaus,Shehu Abdullah,Silber Eli,Young Carolyn,Zajicek John

Publisher

BMJ

Subject

Neurology (clinical),General Medicine

Reference31 articles.

1. HSC 2002/004—Cost effective provision of disease modifying therapies for people with Multiple Sclerosis. Health Do. London. 2002.

2. Disease modification in multiple sclerosis: an update;Rice;Pract Neurol,2014

3. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial;Vermersch;Mult Scler,2014

4. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial;Mikol;Lancet Neurol,2008

5. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis;Fox;N Engl J Med,2012

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Examining the relative contribution of slow-burning inflammation and chronic demyelination to axonal damage in chronic multiple sclerosis lesions;Multiple Sclerosis and Related Disorders;2024-10

2. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-05

3. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption;Journal of Neurology;2024-04-14

4. The Smoothened agonist SAG Modulates the Male and Female Peripheral Immune Systems Differently in an Immune Model of Central Nervous System Demyelination;Cells;2024-04-13

5. Ofatumumab in clinical practice;Neurologie pro praxi;2024-03-06